ABT and ISRG Related Headlines
Go Back- Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
- Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'
- This MedTech stock is 'a strong buy under $500': Bernstein
- Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
